Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03656744
Other study ID # HTD1801.PCT012
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date November 26, 2018
Est. completion date March 9, 2020

Study information

Verified date November 2021
Source HighTide Biopharma Pty Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Randomized, double-blind, placebo-controlled, parallel-group study comparing multiple doses of HTD1801 to placebo.


Description:

This 18-week randomized, double-blind, parallel-group, proof of concept (POC), dose-ranging study compared multiple doses of HTD1801 to placebo in a 1:1:1 ratio. Since accumulation of hepatic fat is considered the "first hit" in the pathogenesis of NASH (Adams and Angulo 2006), change in liver fat content (LFC) by magnetic resonance imaging estimated proton density fat fraction (MRI-PDFF) is an appropriate primary endpoint and is consistent with that used in other recent Phase 2 POC studies in NASH (Harrison et al., 2018, Madrigal Pharmaceuticals 2018). The Harrison et al., 2018, Madrigal Pharmaceuticals 2018 study showed clinically meaningful absolute and relative reductions in LFC assessed by MRI-PDFF over 12-week treatment periods thus, it was considered that an 18 week HTD1801 treatment period would therefore be adequate to assess the study's primary endpoint and to maximize collection of exposure and safety related data.


Recruitment information / eligibility

Status Completed
Enrollment 101
Est. completion date March 9, 2020
Est. primary completion date February 7, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Clinical diagnosis of NASH as assessed by MRI - Clinically documented diagnosis of T2DM - Body mass index (BMI) >25 kg/m2 Exclusion Criteria: - Liver disease unrelated to NASH - Poorly controlled T2DM or Type 1 Diabetes Mellitus - History of alcohol or substance abuse or dependence - Inability to undergo MRI for any reason - History of significant cardiovascular disease

Study Design


Intervention

Drug:
HTD1801
HTD1801 tablets, 250mg
Placebo
tablets manufactured to mimic HTD1801 tablets

Locations

Country Name City State
United States Pinnacle Clinical Research Austin Texas
United States Excel Medical Clinical Trials Boca Raton Florida
United States Institute for Liver Health Chandler Arizona
United States Doctors Hospital at Renaissance Edinburg Texas
United States Cumberland Research Associates Fayetteville North Carolina
United States Gastro One Germantown Tennessee
United States Digestive Health Research Hermitage Tennessee
United States Kansas City Research Institute Kansas City Missouri
United States Florida Research Institute Lakewood Ranch Florida
United States Compass Research Orlando Florida
United States National Research Institute Panorama City California
United States Pinnacle Clinical Research San Antonio Texas
United States Harborview Medical Center Seattle Washington
United States University of Washington Medical Center Seattle Washington
United States Texas Digestive Disease Consultants Southlake Texas
United States Adobe Clinical Research Tucson Arizona
United States Institute for Liver Health Tucson Arizona

Sponsors (1)

Lead Sponsor Collaborator
HighTide Biopharma Pty Ltd

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Absolute Change in Liver Fat Content (LFC) as Measured by MRI-PDFF The primary endpoint was the absolute change in liver fat content (LFC) as measured by magnetic resonance imaging derived proton density fat fraction (MRI-PDFF) from Baseline to Week 18. Baseline through study Week 18
Secondary Change in Fasting Glucose Change in fasting glucose from Baseline to Week 18 . Baseline through study Week 18
Secondary Changes in Hemoglobin A1c Changes in HbA1c from Baseline to Week 18. Baseline through study week 18
Secondary Proportion of Subjects Who Achieved = 30% Relative Reduction in LFC as Measured by MRI-PDFF Proportion of subjects who achieved = 30% relative reduction in liver fat content (LFC) as measured by magnetic resonance imaging derived proton density fat fraction (MRI-PDFF) from Baseline to Week 18. Baseline through study week 18
Secondary Relative Change in LFC as Measured by MRI-PDFF Relative change in liver fat content (LFC) as measured by magnetic resonance imaging derived proton density fat fraction (MRI-PDFF) from Baseline to Week 18. Baseline through study week 18
Secondary Number of Subjects Who Normalized LFC to <5% as Measured by MRI-PDFF Number of subjects who normalized liver fat content (LFC) to <5% as measured by magnetic resonance imaging derived proton density fat fraction (MRI-PDFF) at Week 18. Baseline through study Week 18
Secondary Number of Subjects Who Achieved =5% Absolute Reduction in Liver Fat Content (LFC) as Measured by MRI-PDFF Number of subjects who achieved =5% absolute reduction in liver fat content (LFC) as measured by magnetic resonance imaging derived proton density fat fraction (MRI-PDFF) from Baseline to Week 18. Baseline through study Week 18
Secondary Change in HOMA-IR Change in homeostasis model assessment-estimated insulin resistance (HOMA-IR) from Baseline to Week 18. The higher the HOMA-IR score, the more insulin resistant a person is. Values of <1 are considered optimal while values >2.9 indicate significant insulin resistance. Baseline through study week 18
Secondary Change in LDL-c Change in low-density lipoprotein cholesterol (LDL-c) from Baseline to Week 18. Baseline visit through study week 18
Secondary Change in Serum Triglycerides Change in serum triglycerides from Baseline to Week 18. Baseline through study week 18
Secondary Change in HDL-c Change in high-density lipoprotein cholesterol (HDL-c) from Baseline to Week 18. Baseline through study week 18
Secondary Change in AST Absolute change in aspartate aminotransferase (AST) from Baseline to Week 18. Baseline through study week 18
Secondary Change in ALT Absolute change in alanine aminotransferase (ALT) from Baseline to Week 18. Baseline through study week 18
Secondary Proportion of Subjects With Elevated ALT at Baseline Who Normalized ALT at Week 18 Proportion of subjects with elevated alanine aminotransferase (ALT) at Baseline who normalized ALT at Week 18. Baseline through study week 18
Secondary Change in Pro-Peptide of Type III Collagen (Pro-C3) Change in Pro-C3 from Baseline to Week 18 for subjects with elevated Pro-C3 at Baseline. Baseline through study week 18
Secondary Change in ELF Score Change in the enhanced liver fibrosis (ELF) score. The ELF score is calculated using a published algorithm combining the values of a set of extracellular matrix markers, including TIMP-1, PIIINP, and HA. The ELF score has been reported to show good correlations with fibrosis stages in chronic liver disease, with higher ELF scores associated with higher fibrosis stages. The ELF score is hence used as a prognostic marker for disease progression: ELF score < 9.8 : Low risk of progression, ELF score 9.8 to < 11.3 : Moderate risk of progression and ELF score > = 11.3 : High risk of progression. Baseline through study week 18
Secondary Change in TIMP-1 Change in tissue inhibitor of metalloproteinases 1 (TIMP-1) from Baseline to Week 18. Baseline through study week 18
Secondary Change in PIIINP Change in N-terminal pro-peptide of type III collagen (PIIINP) from Baseline to Week 18. Baseline through study week 18
Secondary Change in HA Change in hyaluronic acid (HA) from Baseline to Week 18. Baseline through study week 18
Secondary Change in Total Bile Acids Changes in total bile acids from Baseline to Week 18. Baseline through study week 18
Secondary Change in FGF19 Change in fibroblast growth factor 19 (FGF19) from Baseline to Week 18 Baseline through study week 18
Secondary Number of Participants Reporting an Adverse Events From Baseline Through Week 18 AEs were mapped to MedDRA version 20.1 preferred term (PT) and system organ class (SOC). If the subject experienced multiple events that mapped to a single preferred term, the greatest severity grade according to CTCAE Version 4.0, and strongest investigator assessment of relation to study medication was assigned to the preferred term. If an event had a missing severity or relationship, it was classified as having the highest severity and/or strongest relationship to study medication. The occurrence of TEAEs was summarized by treatment group by SOC, PT, and severity. Separate summaries of treatment-emergent serious adverse events (SAEs), TEAEs related to study drug, severe or life threatening TEAEs, and TEAEs leading to the discontinuation of study treatment were generated. Additionally, the occurrence of liver-specific AEs was summarized by treatment group. All reported adverse events were listed for individual subjects showing verbatim term, PT and SOC. Adverse events were collected from the time the subject signed the informed consent form through the date of the last visit for a specific subject, that is, approximately 24 weeks in total for a completed subject.
See also
  Status Clinical Trial Phase
Completed NCT06101433 - The Effect of Soy Isoflavones on Non-alcoholic Fatty Liver Disease and the Level of FGF-21 and Fetuin A N/A
Completed NCT03289897 - Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan N/A
Active, not recruiting NCT05479721 - LITMUS Imaging Study
Completed NCT05527938 - Web-based Interventions on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Children N/A
Recruiting NCT06308757 - Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis N/A
Completed NCT02654977 - CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy Phase 2
Completed NCT02927184 - Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease Phase 2
Completed NCT06047847 - Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption N/A
Active, not recruiting NCT03534908 - Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: the Correlation Analysis and Risk Prediction Model Study
Recruiting NCT06098417 - Biomarkers in the Diagnosis and Prognosis of NAFLD
Recruiting NCT04564391 - Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins N/A
Not yet recruiting NCT05984745 - Effect of CoQ10 on the Outcome of MAFLD Patients Phase 2
Not yet recruiting NCT05052515 - The Effects of Natural Extracts Supplementation on NASH Patients N/A
Recruiting NCT02459496 - Diabetes Nutrition Algorithms in Patients With Overt Diabetes Mellitus N/A
Completed NCT01936779 - Understanding the Role of Dietary Fatty Acids on Liver Fat Metabolism in Humans N/A
Completed NCT05844137 - Improving Detection and Evidence-based Care of NAFLD in Latinx and Black Patients With Type 2 Diabetes N/A
Recruiting NCT04664036 - Prevalence, Incidence and Characteristics of NAFLD/NASH in Type 1 Diabetes Mellitus
Recruiting NCT04976283 - Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver Phase 4
Recruiting NCT03587298 - Use of Shear Wave Elastography to Assess Non-alcoholic Fatty Liver Disease (NAFLD)
Completed NCT02952170 - Impact of Weight Loss Surgery in Adolescents With NAFLD N/A